Projekt: „MoBiDik“
Modular bioproduction - disposable and continuous
General description of the project:
Biotechnology is booming with double-digit growth rates. In particular, North Rhine-Westphalia is developing very dynamically and 40% of the German turnover within the field of biotechnology is generated in this part of the country. The optimization of bioprocess technology is crucial for the development and production of novel biopharmaceuticals that have a more patient- and disease-specific mode of action. In addition, much faster, more flexible and cost efficient production technologies and strategies are needed. As a result, a consortium of nine partners (including Bayer Technology Services GmbH, Bayer Schering Pharma AG, Pharmedartis and more University research institutes) in North Rhine-Westphalia has joined in this Hightech.NRW project to bring about a paradigm shift in the bio-process technology. Within the scope of this project, future-oriented, modular, flexible and continuous process technologies in the field of biotechnology will be developed. The project objectives are reflected as follows in the acronym "MoBiDiK".
A) modularity - Biotechnological equipment of the future must react to more frequent product changes and changing needs of quantities in a flexible and cost-effective way. Small and medium-sized biotech enterprises can grow into viable entrepreneurial risk in the biopharmaceutical production.
B) disposable technologies must be made available across the entire process chain and be integrated via intelligent interface management.
C) continuous process technology must be used for process intensification, reduction of cycle times and cost reduction for additives.
Goals of the project
- Focusing on the generation of monoclonal antibodies and derivatives thereof as a therapeutically and commercially significant substance class
- Downstream processing across the entire process chain
- Modern methods of process control
- Demonstration of innovative process technologies
The task of EMI:
In close cooperation with the company of Pharmedartis (Aachen), we will develop a production process for various antibody-based fusion proteins. In addition, various modifications will be integrated into the protein constructs and evaluated for their suitability to achieve increased fermentation yields, constant stability and biological activity. The fermentation process will be optimized using the proprietary systems of the company of Pharmedartis and subsequently adapted to valid GMP regulations.
